International Stem Cell CorpOTCQB:ISCO
- LAST PRICE0.0712
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0611/ 100
- Ask / Lots0.1090/ 87
- Open / Previous Close0.0000 / 0.0712
- Day Range---
- 52 Week Range
- Volume51
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
International Stem Cell Corp | 569.9K | -4.3x | --- |
Fresh Tracks Therapeutics Inc | 5.4M | -0.7x | --- |
Globeimmune Inc | 10.0 | 0.0x | --- |
Rosetta Genomics Ltd | 590.0 | 0.0x | --- |
Pulmatrix Inc | 7.2M | -0.5x | --- |
Stemcell Holdings Inc | 1.6M | 750.0x | --- |
Company Information
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Contact Information
- Headquarters
- 5950 Priestly DrCARLSBAD, CA, United States 92008-8849
- Phone
- 760-940-6383
- Fax
- 302-636-5454
Executives
- Co-Chairman of the Board, Chief Executive Officer
- Andrey Semechkin
- Independent Co-Chairman of the Board, CEO and President of SIS, Inc.
- Donald Wright
- Executive Vice President, Chief Scientific Officer
- Russell Kern
- Independent Investor
- Paul Maier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $569.9K |
|---|---|
Revenue (TTM) | $7.8M |
Shares Outstanding | 8.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-0.02 |
Book Value | $0.01 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | 9.0x |
Operating Margin | -8.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
